Merrill reiterates New River at buy

New River Pharmaceuticals Inc. was reiterated at a buy rating by Merrill Lynch analyst David Munno on Merrill's belief there is limited risk to the NRP104 New Drug Application from this week's Food and Drug Administration panel of cardiovascular safety of amphetamine and stimulant-based ADHD drugs. New data is expected to be presented on Tuesday from the phase 1/2 trial of NRP290, a hydrocodone derivative for acute pain. Shares of the Radford, Va., pharmaceutical company were up 76 cents, or 2.29%, at $34.02 on volume of 159,158 shares versus the three-month running average of 262,936 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.